These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33598901)

  • 1. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals.
    Diel R; Schaberg T; Nienhaus A; Otto-Knapp R; Kneitz C; Krause A; Fabri M; Mrowietz U; Bauer T; Häcker B
    Pneumologie; 2021 Apr; 75(4):293-303. PubMed ID: 33598901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.
    Goletti D; Petrone L; Ippolito G; Niccoli L; Nannini C; Cantini F
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):501-512. PubMed ID: 29848120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
    Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.
    Cantini F; Niccoli L; Capone A; Petrone L; Goletti D
    Expert Opin Drug Saf; 2019 May; 18(5):415-425. PubMed ID: 31066297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.
    Noguera-Julian A; Calzada-Hernández J; Brinkmann F; Basu Roy R; Bilogortseva O; Buettcher M; Carvalho I; Chechenyeva V; Falcón L; Goetzinger F; Guerrero-Laleona C; Hoffmann P; Jelusic M; Niehues T; Ozere I; Shackley F; Suciliene E; Welch SB; Schölvinck EH; Ritz N; Tebruegge M
    Clin Infect Dis; 2020 Dec; 71(10):2561-2569. PubMed ID: 31796965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries.
    Padmapriyadarsini C; Sachdeva KS; Nair D; Ramachandran R
    Expert Rev Respir Med; 2021 Jul; 15(7):899-910. PubMed ID: 33302729
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations.
    Iannone F; Cantini F; Lapadula G
    J Rheumatol Suppl; 2014 May; 91():41-6. PubMed ID: 24788999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
    Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
    Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonist Therapy.
    Jung YJ; Woo HI; Jeon K; Koh WJ; Jang DK; Cha HS; Koh EM; Lee NY; Kang ES
    PLoS One; 2015; 10(10):e0141033. PubMed ID: 26474294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of latent tuberculosis infection research to inform programmatic management in Ireland.
    O'Connell J; de Barra E; McConkey S
    Ir J Med Sci; 2022 Aug; 191(4):1485-1504. PubMed ID: 34595689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.